Pulmonx (LUNG) vs QTREX Quantum (QTEX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Pulmonx (LUNG) has outperformed QTREX Quantum (QTEX) over the past year, gaining 78.5% versus a gain of 9.3%. Over five years, QTEX leads with a -69.7% price change compared with -92.4% for LUNG. Pulmonx is the larger company by market cap ($111.9 million vs $70.6 million), about 1.6 times the size.
Pulmonx converts more of its revenue into profit, with a net margin of -59.7% versus -4574.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LUNG | QTEX |
|---|---|---|
| Share price | $2.57 | $1.00 |
| Market cap | $111.93M | $70.63M |
| 1-day change | -6.20% | -10.71% |
| YTD return | +16.29% | +11.11% |
| 1-year return | +78.47% | +9.29% |
| 5-year return | -92.39% | -69.70% |
| EPS (TTM) | $-1.01 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $90.50M | $289.00K |
| Revenue growth (YoY) | +8.01% | — |
| Net income (latest FY) | $-54.00M | $-13.22M |
| Gross margin | 74.19% | 0.69% |
| Operating margin | -59.30% | -4713.84% |
| Net margin | -59.67% | -4574.39% |
| 52-week high | $3.25 | $3.85 |
| 52-week low | $1.13 | $0.283 |
| Distance from 52-week high | -20.92% | -74.03% |
| Analyst consensus | none | none |
| Avg. price target upside | +65.37% | +400.00% |
| Average volume | 641.52K | 9.21M |
| Shares outstanding | 43.55M | 70.63M |
| Employees | 296 | 34 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LUNG has outperformed QTEX by 69.2 percentage points over the past year.
- Pulmonx is more profitable, keeping -59.7 cents of every revenue dollar as net income versus -4574.4 cents for QTREX Quantum.
About Pulmonx
LUNG stock →Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Health Care · Medical/Dental Instruments · 296 employees
About QTREX Quantum
QTEX stock →QTREX Quantum Ltd., engages in the research, development, manufacturing, and marketing of proprietary life support technologies for the treatment of acute respiratory failure and advanced connectivity solutions for the quantum computing industry in Israel and USA. It offers INSPIRA ART100, a life support system used in procedures requiring cardiopulmonary bypass for six hours or less.
Health Care · Medical/Dental Instruments · 34 employees
LUNG vs QTEX FAQ
Which is bigger, Pulmonx or QTREX Quantum?
Pulmonx (LUNG) is larger, with a market capitalization of $111.93M compared with $70.63M for QTREX Quantum (QTEX).
Which stock has performed better over the past year, LUNG or QTEX?
LUNG returned +78.47% over the past 12 months, compared with +9.29% for QTEX (price return, excluding dividends). Past performance does not predict future results.
Are Pulmonx and QTREX Quantum in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.